Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

Behavioural Brain Research
H Y Meltzer, T Sumiyoshi

Abstract

Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. This impairment is diffuse and may reflect abnormalities in frontal cortex, hippocampus and other brain regions. While deficits in glutamatergic, GABAergic, dopaminergic and cholinergic impairment have received the most attention as the basis of this impairment, there are many reasons for considering the role of serotonin (5-HT) in contributing to these deficits. This may be via its influence on dopaminergic, cholinergic, glutamatergic and GABAergic function, as well as various growth factors that have been implicated in schizophrenia. Of the 14 known serotonin receptors, the 5-HT(1A) receptor is a key candidate for mediating at least some of the influence 5-HT has on cognition. 5-HT(1A) receptors are upregulated in postmortem specimens from patients with schizophrenia, suggesting a deficit in 5-HT(1A) function in this disorder. Atypical but not typical antipsychotic drugs stimulate the efflux of dopamine from cortex by a 5-HT(1A)-dependent mechanism. A series of studies from this laboratory involving the 5-HT(1A) partial agonists tandospirone and buspirone have reported a modest ability of these agents ...Continue Reading

References

Feb 1, 1990·Journal of Clinical Psychopharmacology·D BrodyJ Rotrosen
Jun 1, 1991·Journal of Clinical Psychopharmacology·D C GoffE T Amico
Feb 1, 1989·Journal of Clinical Psychopharmacology·R Sovner, N Parnell-Sovner
Jan 1, 1996·Journal of Neural Transmission·H Y Meltzer, M Maes
Oct 6, 1997·Biological Psychiatry·E V Gurevich, J N Joyce
Mar 30, 2001·Journal of Psychopharmacology·R A BantickP M Grasby
Jul 31, 2001·Journal of Clinical Psychopharmacology·P SirotaS Kindler
Oct 2, 2001·The American Journal of Psychiatry·T SumiyoshiH Y Meltzer
Dec 14, 2002·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Siegfried KasperThomas Brücke
Feb 4, 2003·The American Journal of Psychiatry·Fumihiko YasunoKazutoshi Suzuki
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Aug 3, 2004·The American Journal of Psychiatry·Tomiki Sumiyoshi, Herbert Y Meltzer
Mar 24, 2005·The International Journal of Neuropsychopharmacology·Neil D WoodwardDavid H Zald
Jun 10, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eunice Y YuenZhen Yan
Sep 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Martijn MeeterWim J Riedel
Nov 23, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tsuyoshi ArakiKiyoto Kasai
Nov 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Llorenç Díaz-MataixFrancesc Artigas
Apr 28, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeJeffrey A Lieberman
Jul 1, 2006·Psychopharmacology·Robert S KernRon Marcus
Mar 3, 2007·Journal of Psychopharmacology·Samuel R ChamberlainBarbara J Sahakian
Mar 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomiki SumiyoshiMasayoshi Kurachi
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Dec 28, 2007·Pharmacological Reviews·Klaus B Fink, Manfred Göthert
Jan 16, 2008·Proceedings of the National Academy of Sciences of the United States of America·Vera Bubenikova-ValesovaKarel Vales

❮ Previous
Next ❯

Citations

Sep 4, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Benoit LabonteGabriella Gobbi
Nov 5, 2011·Epilepsia·William H TheodoreSusumu Sato
Oct 31, 2008·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Armida MucciSilvana Galderisi
Dec 7, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Alessia LuoniMarco A Riva
Jan 16, 2014·Neurobiology of Learning and Memory·Rudy Schreiber, Adrian Newman-Tancredi
Apr 11, 2014·Journal of Clinical Psychopharmacology·Tomiki Sumiyoshi
Sep 13, 2014·European Archives of Psychiatry and Clinical Neuroscience·Mathias ZinkAndrea Schmitt
Nov 26, 2011·Expert Review of Clinical Pharmacology·Aravind Mittur
Apr 12, 2011·Expert Opinion on Drug Metabolism & Toxicology·Silvio Caccia
Nov 12, 2009·Pharmacological Reports : PR·Małgorzata Filip, Michael Bader
Oct 2, 2015·Metabolic Brain Disease·S T KimaniP G Kioy
Sep 6, 2011·Neuroscience Letters·Xiaofeng GuoUNKNOWN Early-stage Schizophrenia Outcome Study (ESOS) Investigators
Aug 6, 2011·European Journal of Medicinal Chemistry·Tomasz SłowińskiFranciszek Herold
Mar 16, 2011·Neuroscience and Biobehavioral Reviews·Dave J Hayes, Andrew J Greenshaw
Nov 3, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·B CapuanoW W Blessing
Oct 13, 2015·Progress in Neurobiology·Yukihiro OhnoMasashi Sasa
Jun 18, 2014·CNS Neuroscience & Therapeutics·Vladimir S NaumenkoEvgeni G Ponimaskin
Jan 21, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Noriko YoshimiKenji Hashimoto
Jun 26, 2013·Nordic Journal of Psychiatry·Chin-Bin YehChih-Ken Chen
Aug 3, 2014·Molecular Neurobiology·N K PopovaV S Naumenko
Mar 26, 2015·Behavioural Brain Research·Satoko BabaKazuhito Ikeda
Feb 18, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Tamaki IshimaKenji Hashimoto
Jan 28, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Naohisa TsujinoMasafumi Mizuno
Aug 3, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Darakhshan Jabeen Haleem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.